United Therapeutics Corporation (UTHR) Analyst Ratings & Price Targets

United Therapeutics Corporation

UTHR · Nasdaq

Analyst Consensus

Buy

15 analysts

$593

Current

—

Low

$699

Average

—

High

Average target implies +17.82% versus the current price.

Analyst Ratings Synthesis

The published analyst picture is inconsistent with the supplied top-line consensus field, which is unknown: StockAnalysis reports 14 covering analysts and an aggregate Buy rating, with a $561.57 average target, while other pages cite $638.80 and $648.33 averages. Targets cluster broadly between $561.57 and $648.33, but the stated range is $302 to $648.33, a $346.33 spread. BofA Securities is the least bullish named stance, retaining Neutral while cutting its target to $613 from $620; no named analyst is identified as the most bullish. The direction of revisions over the past week cannot be established because dates and a dated revision history were not supplied. The substantive disagreement is valuation versus pipeline and product upside.

Symbol: UTHR
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: North America
Exchange: Nasdaq

Founded by CEO Martine Rothblatt to discover a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics transforms the treatment of rare diseases and pioneers alternatives to expand the supply of transplantable organs. From our innovative therapies to our groundbreaking manufactured organs, we are bold and unconventional. We move quickly from scientific theory to practical technologies that can save lives. As a public benefit corporation, even our legal structure reflects our commitments. We serve patients, act with integrity, create long-term shareholder value, and operate with sustainable practices that protect the future we are working to build.

Key Issues

Bullish view

The announced accelerated repurchase and reported $477.6 million authorization, within coverage describing a potential $4 billion shareholder-return program, indicate substantial cash-generation capacity and may support per-share value.

Bearish view

Large shareholder returns could compete with the capital required to advance United Therapeutics’ pipeline, which is the central concern raised by coverage asking whether pipeline funding can keep pace.